US Pharmaceutical Pricing Policies: A Systemic Analysis of the Trump Administration's Impact on Healthcare Costs
Original framing: “[World Report] Are Trump's drug pricing policies saving anyone money?” — The Lancet
The history of pharmaceutical pricing in the US is marked by a series of laws and regulations that have favored the interests of pharmaceutical companies over those of patients. For example, the 1984 Hatch-Waxman Act allowed pharmaceutical companies to extend their patent protections, leading to a surge in prices for essential medications. By examining the historical context of pharmaceutical pricing, we can better understand the systemic causes of high healthcare costs.
The US pharmaceutical pricing system is characterized by a complex web of power dynamics, historical precedents, and systemic causes.
By examining the perspectives of marginalized communities, incorporating alternative approaches to healthcare, and reforming patent laws and regulations, the US can develop a more equitable and effective pharmaceutical pricing system. This approach would prioritize the well-being of individuals and communities over the pursuit of profit, and would lead to significant reductions in healthcare costs and improved access to essential medications.